Estrogen — a potential treatment for schizophrenia

@article{Kulkarni2001EstrogenA,
  title={Estrogen — a potential treatment for schizophrenia},
  author={Jayashri Kulkarni and A. Riedel and Anthony R. de Castella and Paul B. Fitzgerald and Timothy Rolfe and J. B. Taffe and Henry Burger},
  journal={Schizophrenia Research},
  year={2001},
  volume={48},
  pages={137-144}
}
Estrogen has been shown in animal studies to modulate both the dopamine and serotonin neurotransmitter systems - the main neurotransmitters implicated in the pathogenesis of schizophrenia. A double blind, 28 day, placebo-controlled study was conducted with three groups of women of child-bearing age (N=12 in each group) who received standardized antipsychotic medication plus 50mcg transdermal estradiol or 100mcg transdermal estradiol or transdermal placebo. Analyses show that women receiving… Expand

Paper Mentions

Interventional Clinical Trial
The efficacy of raloxifene versus placebo was compared over a six-month period, as an adjuvant treatment of the negative symptoms of schizophrenia in a group of 80 post-menopausal… Expand
ConditionsNegative Symptoms of Schizophrenia in Post-menopausal Women.
InterventionDrug
Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: a double-blind, randomized, placebo-controlled clinical trial.
TLDR
Estrogen may be an effective adjuvant agent in the treatment of women with chronic schizophrenia and showed a significant decrease in positive, negative, general, general and total PANSS scores over 4 weeks. Expand
Role of Estrogen Treatment in the Management of Schizophrenia
TLDR
An overview of different applications of adjunctive estrogen as a possible treatment for symptoms of schizophrenia in both men and women is provided. Expand
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial
TLDR
The results of this study suggest that estrogen may be an effective adjuvant agent in the management of women of childbearing age with chronic schizophrenia, Nevertheless, results of larger controlled trials are needed before recommendation for a broad clinical application can be made. Expand
Relationship between estrogen and schizophrenia
  • A. Mortimer
  • Psychology, Medicine
  • Expert review of neurotherapeutics
  • 2007
TLDR
The advent of specific estrogen receptor modulators will have little to add to schizophrenia treatment if estrogen is, essentially, devoid of any specific antipsychotic or adjuvant mechanism of action relevant to the pathophysiology of this disorder. Expand
A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings
TLDR
This review comprehensively analyse studies that have investigated the effects of estrogen, in particular 17β-estradiol, in clinical, animal, and molecular research with relevance to schizophrenia to discuss the current evidence on estrogen dysfunction in schizophrenia patients and review the clinical findings on the use of estradiol as an adjunctive treatment in schizophrenia Patients. Expand
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
TLDR
Raloxifene as an adjuvant treatment in postmenopausal women with schizophrenia who exhibit prominent negative symptoms appears to be useful in improving negative, positive, and general psychopathological symptoms. Expand
The Role of Estrogen in the Treatment of Men with Schizophrenia
TLDR
Findings do, however, suggest that further exploration of a therapeutic role for adjunctive estradiol treatment in men with schizophrenia is warranted, and the development of the new estrogen compounds which do not cause feminisation opens up the possibility of using a different type of estrogen for a longer period of time at higher doses. Expand
Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study
In a double-blind, placebo controlled study, conjugated estrogens (CE) (0.625 mg/day) were added to a fixed dosage of haloperidol (5 mg daily). Forty-four female inpatients with acute schizophreniaExpand
Estrogen augmentation in schizophrenia: A quantitative review of current evidence
TLDR
The results suggest that estrogens, especially estradiol, could be an effective augmentation strategy in the treatment of women with schizophrenia, however, future larger trials are needed before recommendations on clinical applications can be made. Expand
A clinical trial of adjunctive oestrogen treatment in women with schizophrenia
TLDR
Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50‬μg est radiol or placebo groups, and may prove clinically useful in the overall treatment of women with schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
A clinical trial of the effects of estrogen in acutely psychotic women
TLDR
The results suggest that estradiol may have antipsychotic properties and/or act as a catalyst for neuroleptic responsiveness in women with schizophrenia. Expand
Modulation of dopamine receptor sensitivity by estrogen.
TLDR
Preliminary data indicate that estrogen can attenuate the development or mask the display of the supersensitive dopamine receptor in tardive dyskinesia and show an attenuation of drug-induced stereotypy. Expand
An animal model for the effects of estradiol on dopamine-mediated behavior: Implications for sex differences in schizophrenia
TLDR
It is suggested that estradiol might act as a protective modulator in schizophrenia by enhancing the vulnerability threshold for psychosis through the downward regulation of DA neurotransmission. Expand
Neuroendocrine response to antipsychotics: effects of drug type and gender
TLDR
Amisulpride's more pronounced endocrine effects may be a reflection of its distinguished pharmacology and pharmacokinetics. Expand
Modulation of brain dopamine transmission by sex steroids.
TLDR
A better understanding of steroid-dopamine interactions and the possible isolation of conditions to have only pro or anti dopaminergic activity could then be used to develop combined therapies or to optimize drug treatments that would take into account the patient's sex and endocrine status. Expand
The role of estrogens in schizophrenia gender differences.
TLDR
The hypothesis of this article is that estrogens, either directly or indirectly, modify symptom expression and account for many of the observed gender differences in schizophrenia. Expand
Effect of prolactin and estradiol on rat striatal dopamine receptors.
TLDR
The present data indicate that high prolactin levels lead to an increased density of striatal dopamine receptors, however, the effect of estradiol may not be explained exclusively by increased prolact in levels since a similar stimulatory effect is observed in hypophysectomized animals. Expand
The role of estrogen in schizophrenia.
  • M. Seeman
  • Psychology, Medicine
  • Journal of psychiatry & neuroscience : JPN
  • 1996
TLDR
High levels of estrogens protect against symptom exacerbations in women with schizophrenia, and neuroleptic doses could be reduced at certain times of the month and increased at others. Expand
Testosterone as well as estrogen increases serotonin2A receptor mRNA and binding site densities in the male rat brain.
TLDR
The lack of effect of 5alpha-DHT, a potent androgen which cannot be converted to estrogen, suggests that the action of testosterone depends upon its conversion to estrogen by aromatase, and may also explain why estrogen increased the density of 5-HT2AR binding sites in the caudate-putamen, a brain region where aromat enzyme is scarce. Expand
Sex Differences and Effects of Estrogen on Dopamine and DOPAC Release from the Striatum of Male and Female CD-1 Mice
TLDR
Clear sex differences in striatal dopamine turnover and concentrations under conditions of equal hormonal status are demonstrated and estrogen can exert substantial effects on Striatal dopamine metabolism by acting specifically in females to increase neuronal dopamine synthesis and release without depleting dopamine content are indicated. Expand
...
1
2
3
...